The EMBO J:研究者揭示慢性疼痛中天然蛋白质14-3-3ζ的重要作用

2012-06-17 T.Shen 生物谷

近日,来自法国和瑞典的研究者发现大鼠机体的蛋白质是如何介导产生慢性疼痛感的。相关研究成果刊登在了国际著名杂志EMBO Journal上。慢性疼痛具有持续性,而且经常很难处理,部分是因为神经元分子信号发生的改变,这种改变最终会破坏神经信号从脊椎到大脑的传递。研究者Marc表示,他们运用一系列的技术更精确地从分子水平来研究导致动物慢性疼痛的分子机制。 研究结果揭示了天然蛋白质14-3-3ζ在慢性疼痛

近日,来自法国和瑞典的研究者发现大鼠机体的蛋白质是如何介导产生慢性疼痛感的。相关研究成果刊登在了国际著名杂志EMBO Journal上。慢性疼痛具有持续性,而且经常很难处理,部分是因为神经元分子信号发生的改变,这种改变最终会破坏神经信号从脊椎到大脑的传递。研究者Marc表示,他们运用一系列的技术更精确地从分子水平来研究导致动物慢性疼痛的分子机制。

研究结果揭示了天然蛋白质14-3-3ζ在慢性疼痛的大鼠脊椎中水平较高,而且研究者揭示了14-3-3ζ蛋白质可以引发信号途径的改变进而引发慢性疼痛症状出现。14-3-3ζ蛋白质可以破坏GABA-B受体两个亚基之间的相互作用,GABA-B受体是在神经细胞表面发现的蛋白质复合物。GABA-B受体是G蛋白偶联受体。研究者使用抗体标记和显微镜技术来研究信号蛋白之间的分子反应,在细胞和活的动物体内,研究者揭示了14-3-3ζ蛋白质可以直接和GABA-B受体的B1亚基反应,这种反应损害了受体的信号效用,而且限制了疼痛感的释放。

研究者同时也揭示了用一种特殊的小感染RNA(siRNA)技术或者竞争肽来治疗大鼠的疗法。通过14-3-3ζ蛋白质引发的GABA-B受体损伤对于调节慢性疼痛是一种新的机制。研究者表示,我们可以用抑制剂来干扰蛋白质14-3-3ζ的功能,从而提出新的疗法。以GABA-B受体分散过程为靶标也可以成为治疗的靶点,这将使得标准的止痛药发挥更大的药效。(生物谷Bioon.com)

编译自:Naturally Occurring Protein Has Role in Chronic Pain

编译者:T.Shen

doi:10.1038/emboj.2012.161
PMC:
PMID:

Impairment of GABAB receptor dimer by endogenous 14-3-3ζ in chronic pain conditions

Sophie Laffray, Rabia Bouali-Benazzouz, Marie-Amélie Papon, Alexandre Favereaux, Yang Jiang, Tina Holm, Corentin Spriet, Pascal Desbarats, Pascal Fossat, Yves Le Feuvre, Marion Decossas, Laurent Héliot, Ulo Langel, Frédéric Nagy and Marc Landry

In the central nervous system, the inhibitory GABAB receptor is the archetype of heterodimeric G protein-coupled receptors (GPCRs). However, the regulation of GABAB dimerization, and more generally of GPCR oligomerization, remains largely unknown. We propose a novel mechanism for inhibition of GPCR activity through de-dimerization in pathological conditions. We show here that 14-3-3ζ, a GABAB1-binding protein, dissociates the GABAB heterodimer, resulting in the impairment of GABAB signalling in spinal neurons. In the dorsal spinal cord of neuropathic rats, 14-3-3ζ is overexpressed and weakens GABAB inhibition. Using anti-14-3-3ζ siRNA or competing peptides disrupts 14-3-3ζ/GABAB1 interaction and restores functional GABAB heterodimers in the dorsal horn. Importantly, both strategies greatly enhance the anti-nociceptive effect of intrathecal Baclofen in neuropathic rats. Taken together, our data provide the first example of endogenous regulation of a GPCR oligomeric state and demonstrate its functional impact on the pathophysiological process of neuropathic pain sensitization.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032700, encodeId=4b0e2032e00a8, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Jul 06 19:06:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765478, encodeId=b45e1e6547896, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 20 07:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023446, encodeId=5e312023446cd, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 24 03:06:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260004, encodeId=9e6d1260004da, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296855, encodeId=2c371296855c6, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-07-06 stfoxst
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032700, encodeId=4b0e2032e00a8, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Jul 06 19:06:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765478, encodeId=b45e1e6547896, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 20 07:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023446, encodeId=5e312023446cd, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 24 03:06:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260004, encodeId=9e6d1260004da, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296855, encodeId=2c371296855c6, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032700, encodeId=4b0e2032e00a8, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Jul 06 19:06:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765478, encodeId=b45e1e6547896, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 20 07:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023446, encodeId=5e312023446cd, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 24 03:06:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260004, encodeId=9e6d1260004da, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296855, encodeId=2c371296855c6, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032700, encodeId=4b0e2032e00a8, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Jul 06 19:06:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765478, encodeId=b45e1e6547896, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 20 07:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023446, encodeId=5e312023446cd, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 24 03:06:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260004, encodeId=9e6d1260004da, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296855, encodeId=2c371296855c6, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2032700, encodeId=4b0e2032e00a8, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Jul 06 19:06:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765478, encodeId=b45e1e6547896, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 20 07:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023446, encodeId=5e312023446cd, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 24 03:06:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260004, encodeId=9e6d1260004da, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296855, encodeId=2c371296855c6, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]

相关资讯

Sci. Transl. Med.:肽类分子E4带来抗纤维化新希望

5月30日,Sci. Transl. Med.杂志报道,科学家发现一种新的肽类分子E4,可发挥抗器官纤维化功效。纤维增殖异常如先天性肺纤维化和系统性硬化,由于没有有效的治疗手段,常导致进展性器官纤维化进而引发显著的致病和致死率。 为解决这一突出问题,研究者在人类及小鼠模型,体内及体外多个实验条件下,检测了来源于内皮他汀的肽类对已有纤维化以及TGF-β和争光霉素诱发纤维化的效果。 研究发现了,一

Nat.Comm:胰岛素与胰岛素样生长因子作用新进展

人体存在两种脂肪,白色脂肪堆积在皮下,存储多余热量;棕色脂肪负责分解白色脂肪,避免引起肥胖。胰岛素和胰岛素样生长因子1(insulin-like growth factor 1,IGF-1)在脂肪细胞的分化、葡萄糖耐量和胰岛素敏感度的调解中扮演着重要角色。 为了研究机体内胰岛素和IGF-1相关途径是如何协同作用的,研究人员制作了组织特异性基因敲除模型。研究人员在小鼠中同时敲除了胰岛素和IGF-1

Nature:破解自闭症谱系障碍的形成机制

自闭症谱系障碍(Autism spectrum disorder ,ASD)是一组以社交活动受限及交流障碍为特点的发育障碍性疾病,同时伴有行为受限、重复或呈刻板模式等特征。ADS是一种多基因控制的遗传疾病。Shank2编码兴奋性神经突触上的鹰架蛋白,最近的研究表明,人类Shank2突变与自闭症和智力障碍有关。 尽管随着科技进步越来越多与自闭症有关的基因被发现,但探索ASD发病机制与找到行之有效的

Arch Inter Med:避免不必要的医学成像可降低女性患乳腺癌风险

来自美国医学研究所(IOM)的研究揭示了乳腺癌潜在的环境风险因子,包括农药、美妆、家用化学品以及制作水杯的塑料等,IOM表示,目前并没有充足的数据可以揭示暴露于这些风险因子中一定会引发乳腺癌。然而可以增加妇女绝经后激素替代疗法的风险以及接受医学成像暴露辐射的风险。 如今一项刊登在国际著名杂志Archives of Internal Medicine上的研究报告指出IOM的报告中乳腺癌与医学成像有

Sci. Transl. Med.:感染前免疫系统的组成影响SIV感染后疾病进展

5月30日,Sci. Transl. Med.杂志报道,科学家发现感染前免疫系统的组成对猿猴免疫缺陷病毒(SIV)感染后疾病的进展具有显著影响。这为HIV的研究提供了新的线索。 某些HIV患者对该病毒的抵抗性很强,而有些患者则进展迅速。其背后的机制一直不明。病毒和宿主遗传因子,如nef缺失以及主要组织复合物等位基因,可部分解释这种差异性。然而,确定在病毒感染前的,抵抗HIV疾病进展的宿主免疫功能

Cancer Cell:p53在乳腺癌治疗中的角色逆转现有认识

近日,来自国外的研究者研究揭示,肿瘤抑制因子p53的正常存在可以使得以多柔比星为化学疗法的乳腺癌治疗效用更低。相关研究成果刊登在近日的国际杂志Cancer Cell上。这项研究挑战了现有的认知,让我们对于乳腺癌的化学疗法进行了更为深入的认识。 理解肿瘤细胞的遗传缺陷对于治疗疾病非常重要,研究者表示他们的研究成果完全与预期的相反,研究者认为p53基因正常的话,肿瘤细胞应该对于疗法产生更好的反应,然